🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Health Concern

Gonorrhoea infections are increasing globally, with estimates suggesting more than 82 million new cases per year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices currently available.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

Based on findings detailed in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which involves two antibiotics. The study enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians on the front lines have shared optimism. Access to a easy-to-administer therapy such as this is seen as a "critical tool" for gonorrhoea control. This is considered vital to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.